Biogen’s Strategic Collaboration Agreement with Skyhawk Therapeutics
January 04, 2019
On January 4, 2019, Biogen Inc. and Skyhawk Therapeutics, Inc. announced a strategic collaboration in which the companies will leverage Skyhawk’s SkySTAR™ technology platform with the goal of discovering innovative small molecule treatments for patients with neurological diseases. Biogen will have the option to license therapies resulting from the collaboration and will be responsible for their development and potential commercialization. The agreement grants Biogen an exclusive license to worldwide intellectual property rights on research‑stage therapeutic candidates for the treatment of multiple sclerosis, spinal muscular atrophy and additional neurological disorders. Cravath is representing Biogen in connection with the transaction.
The Cravath team is led by partners David J. Kappos and G.J. Ligelis Jr. and includes associates Miling Y. Harrington, Bethany A. Pfalzgraf and Michael L. Arnold on M&A and intellectual property matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 1990, University of California, Berkeley, School of Law
-
B.S., 1983, University of California, Davissumma cum laude
- New York
- California
- District of Columbia
Education
Admitted In
- Photo
-
-
J.D., 2009, Harvard Law Schoolcum laude
-
A.B., 2006, Princeton UniversityPhi Beta Kappa, magna cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 2013, Columbia Law SchoolHarlan Fiske Stone Scholar
-
B.A., 2010, University of ChicagoGeneral Honors
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
July 28, 2023
Biogen’s $7.3 Billion Acquisition of Reata Pharmaceuticals
On July 28, 2023, Biogen Inc. (“Biogen”) and Reata Pharmaceuticals, Inc. (“Reata”) announced that they have entered into a definitive agreement under which Biogen has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Cravath is representing Biogen in connection with the transaction.
